Analysts expect Sunworks, Inc. (NASDAQ:SUNW) to report $-0.05 EPS on April, 4.They anticipate $0.13 EPS change or 72.22% from last quarter’s $-0.18 EPS. After having $-0.09 EPS previously, Sunworks, Inc.’s analysts see -44.44% EPS growth. The stock increased 3.09% or $0.03 during the last trading session, reaching $1. About 116,577 shares traded. Sunworks, Inc. (NASDAQ:SUNW) has declined 25.87% since March 17, 2017 and is downtrending. It has underperformed by 42.57% the S&P500.
Mednax Inc (NYSE:MD) had an increase of 10.52% in short interest. MD’s SI was 3.52M shares in March as released by FINRA. Its up 10.52% from 3.19 million shares previously. With 794,200 avg volume, 4 days are for Mednax Inc (NYSE:MD)’s short sellers to cover MD’s short positions. The SI to Mednax Inc’s float is 3.89%. The stock decreased 0.02% or $0.01 during the last trading session, reaching $57.46. About 800,078 shares traded. MEDNAX, Inc. (NYSE:MD) has declined 18.20% since March 17, 2017 and is downtrending. It has underperformed by 34.90% the S&P500.
Sunworks, Inc. provides photo voltaic based power systems for the agricultural, commercial, industrial, and residential markets in the United States. The company has market cap of $22.46 million. It also designs, finances, integrates, installs, and manages systems ranging in size from 2 kilowatt for residential loads to multi megawatt systems for larger commercial projects. It currently has negative earnings. In addition, the firm offers various installation services, including design, system engineering, procurement, permitting, construction, grid connection, warranty, system monitoring, and maintenance services to its solar energy customers.
MEDNAX, Inc., together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company has market cap of $5.33 billion. The firm offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services. It has a 16.66 P/E ratio. It also provides maternal-fetal care, including inpatient and office clinical care to expectant mothers and their unborn babies through maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians consisting of maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors.
Among 18 analysts covering MEDNAX (NYSE:MD), 5 have Buy rating, 1 Sell and 12 Hold. Therefore 28% are positive. MEDNAX had 50 analyst reports since July 31, 2015 according to SRatingsIntel. JP Morgan initiated the shares of MD in report on Wednesday, September 16 with “Overweight” rating. The firm has “Neutral” rating given on Tuesday, May 30 by Mizuho. The firm earned “Buy” rating on Friday, October 28 by Mizuho. On Wednesday, January 24 the stock rating was maintained by Mizuho with “Hold”. Mizuho maintained it with “Buy” rating and $79 target in Friday, April 29 report. Jefferies downgraded MEDNAX, Inc. (NYSE:MD) on Tuesday, December 13 to “Hold” rating. KeyBanc Capital Markets upgraded the stock to “Overweight” rating in Monday, September 18 report. The stock has “Neutral” rating by Goldman Sachs on Friday, December 9. Piper Jaffray maintained MEDNAX, Inc. (NYSE:MD) on Thursday, February 8 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, March 8 report.